Haemophilia : the official journal of the World Federation of Hemophilia · 2025
In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Josset Laurie, Rezigue Hamdi, Nougier Christophe, Leuci Alexandre, Désage Stéphanie, Lienhart Anne, Dargaud Yesim
Аннотация
INTRODUCTION: Early prophylaxis is the gold standard of care for severe haemophilia. The development of subcutaneous Factor VIII (FVIII) mimetics, such as emicizumab, has significantly reduced the disease burden and improved protection against bleeding episodes. Despite its benefits, emicizumab does not fully normalize haemostasis, requiring additional FVIII treatment for surgical procedures and management of breakthrough bleeding. In these cases, extended or ultra-extended half-life FVIII products are most commonly used. However, laboratory monitoring of these combinations can be challenging.
AIM: This study investigates the in vitro combined haemostatic activity of emicizumab with efmoroctocog alfa and efanesoctocog alfa using a thrombin generation assay (TGA).
RESULTS AND CONCLUSION: TGA can be used to monitor combined treatment with emicizumab and either efmoroctocog alfa or efanesoctocog alfa, which is not possible with currently available FVIII reagents for the latter. As expected, there is no synergistic effect between the mimetic and FVIII at therapeutical doses. Both efmoroctocog alfa and efanesoctocog alfa show similar in vitro procoagulant activity in terms of thrombin generation.
AIM: This study investigates the in vitro combined haemostatic activity of emicizumab with efmoroctocog alfa and efanesoctocog alfa using a thrombin generation assay (TGA).
RESULTS AND CONCLUSION: TGA can be used to monitor combined treatment with emicizumab and either efmoroctocog alfa or efanesoctocog alfa, which is not possible with currently available FVIII reagents for the latter. As expected, there is no synergistic effect between the mimetic and FVIII at therapeutical doses. Both efmoroctocog alfa and efanesoctocog alfa show similar in vitro procoagulant activity in terms of thrombin generation.